EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Gene and Genome-Editing Strategies for Epilepsy: Experimental Advances and Translational Challenges

Bilal Ahmad Seh, Kashf Rafiq, Adam Legradi iD, Mohd Yaqub Mir

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27062845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Bilal Ahmad Seh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02106 Warszawa, Poland. Hauptthemen laut MEDLINE: Gene Editing, Epilepsy, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy affects more than 50 million individuals worldwide, and approximately one-third of patients remain refractory to existing antiseizure medications. Advances in gene therapy and genome editing have opened new possibilities for disease-modifying interventions that directly target the molecular and circuit-level mechanisms underlying epileptogenesis. Recent progress in central nervous system tropic viral vectors, non-viral delivery systems, and programmable genome-editing technologies has enabled precise manipulation of neuronal and glial function in preclinical epilepsy models. Strategies range from restoration of haploinsufficient genes implicated in monogenic epilepsies, such as SCN1A in Dravet syndrome, to modulation of neuronal excitability through engineered ion channels, neuropeptides, and astrocyte-based approaches. In parallel, CRISPR-derived platforms, including transcriptional activation and repression systems, base editing, and prime editing, offer new avenues for regulating gene expression in post-mitotic neurons without introducing double-strand DNA breaks. Despite these advances, significant translational challenges remain, including efficient and cell-type-specific delivery, long-term safety, and the risk of network-level side effects in the epileptic brain. This review critically examines recent gene therapy and genome-editing approaches for epilepsy, highlights key technological and biological barriers to clinical translation, and discusses emerging strategies that may enable durable and targeted treatments for drug-resistant epilepsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingEpilepsyGenetic TherapyHumansAnimalsTranslational Research, BiomedicalCRISPR-Cas Systems

Stichwörter der Autor:innen

CRISPR technologiesdrug-resistant epilepsyepilepsygene therapygenome editing

Autor:innen und Institutionen

  • Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02106 Warszawa, Poland.
  • Institute of Clinical Medicine, Faculty of Health Sciences, University of Eastern Finland, FI-70029 Kuopio, Finland.
  • Department of Cell Biology and Molecular Medicine, University of Szeged, H-6720 Szeged, Hungary.
  • Epilepsy Centre, Department of Clinical Sciences, Lund University Hospital, 221 00 Lund, Sweden.

ORCID-Profile: Adam Legradi

Zitieren

APA

Seh, B. A., Rafiq, K., Legradi, A., & Mir, M. Y. (2026). Targeted Gene and Genome-Editing Strategies for Epilepsy: Experimental Advances and Translational Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062845

Vancouver

Seh BA, Rafiq K, Legradi A, Mir MY. Targeted Gene and Genome-Editing Strategies for Epilepsy: Experimental Advances and Translational Challenges. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062845

BibTeX
@article{Seh2026,
  author = {Seh, Bilal Ahmad and Rafiq, Kashf and Legradi, Adam and Mir, Mohd Yaqub},
  title = {Targeted Gene and Genome-Editing Strategies for Epilepsy: Experimental Advances and Translational Challenges},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27062845}
}
Kostenlos starten →